DAXXIFY®
Conveniently located to serve the areas of New York, NY
DAXXIFY | NOW AVAILABLE
Daxxify is the first and only peptide-powered, FDA-approved frown line treatment designed to minimize the appearance of facial wrinkles, with a median duration of 6 months and up to 9 months for some patients.
Dr. Jennifer Levine is one the first to offer Daxxify in New York City.
Book NowContents
In The Media
As top 1 % injector in the country, Dr. Levine has been selected as one of the first providers in New York City to offer DAXXIFY.
Daxxify vs. Botox: NYC’s Dr. Jennifer Levine sheds light on the New Anti-wrinkle Injectable
What Is DAXXIFY?
Daxxify was developed by the manufacturer Revance Therapeutics. Studies showed the drug can temporarily improve “moderate to severe frown lines” in adults for a median duration of six months, which is up to two months longer than the period generally provided by Botox.
DAXXIFY vs Botox: How Does It Work?
Daxxify and Botox are both acetylcholine release inhibitors and neuromuscular blocking agents. They work by blocking chemical signals from nerves that cause muscles to contract, temporarily relaxing facial muscles and reducing the appearance of wrinkles.
What sets Daxxify apart is its use of peptide exchange technology, which gives it a unique dual-action effect. This technology allows Daxxify to attach to muscle receptors more effectively, leading to longer-lasting results. The peptides also provide skin-boosting benefits, enhancing the overall appearance and health of the skin.
Additionally, Daxxify is often referred to as the “vegan Botox” because it is the only neuromodulator free from human serum albumin and animal-based components.
While Botox typically lasts about 3–4 months, Daxxify can last up to 9 months, with a median duration of 6 months. This extended duration is great news for our patients, offering them longer intervals between treatments.
What Conditions Can DAXXIFY Treat?
In addition to reducing the appearance of fine lines and wrinkles, Daxxify can also used to treat conditions such as neck spasms, excessive sweating, an overactive bladder, and lazy eye.
Daxxify was found to be “generally safe and well tolerated” with no serious treatment-related adverse events reported in during the clinical trials.
FAQ
Contraindications
DAXXIFY™ contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.The potency Units of DAXXIFY™ are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Drug Interactions
Co-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interferinCo-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY™ may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY™ is unknown.
Use in Specific Populations
DAXXIFY™ is not recommended for use in children or pregnant women.Please see DAXXIFY™ full Prescribing Information, including Boxed Warning and Medication Guide.
References
– DAXXIFY™. Prescribing Information. Revance Therapeutics, Inc, 2022.
– Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2021;47(1):48-54.
– BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2020.
– XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021.
– DYSPORT®. Prescribing Information. Ipsen Biopharm Ltd; 2020.
– JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
– Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
– Data on File. Protocols 1620301-303. Post Hoc Analysis. Newark, CA: Revance Therapeutics, Inc, 2021.
– Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845.
